Patents Assigned to PHI PHARMA SA
  • Publication number: 20240108739
    Abstract: The present invention relates to oligomeric compounds comprising at least two peptide moieties that bind specifically to proteoglycans, their payload conjugates and pharmaceutical compositions containing the same. Instant compounds, payload conjugates and pharmaceutical compositions are particularly useful in the treatment of cancer and in diagnostics.
    Type: Application
    Filed: December 18, 2021
    Publication date: April 4, 2024
    Applicant: PHI PHARMA SA
    Inventors: Christoph BONNY, Luc OTTEN, Andreas PEER, Marc MATHIEU, Alessandro ZORZI
  • Patent number: 10174078
    Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, keratan sulfate. The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of keratan-sulfate expressing cells in vitro and in vivo.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: January 8, 2019
    Assignee: PHI PHARMA SA
    Inventors: Christophe Bonny, Fabrice Chenaux, Vincent Zoete
  • Patent number: 10131690
    Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, chondroitin 6-sulfate (C6S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C6S expressing cells in vitro and in vivo.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: November 20, 2018
    Assignee: PHI PHARMA SA
    Inventors: Christophe Bonny, Fabrice Chenaux, Vincent Zoete
  • Patent number: 9688723
    Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides and polypeptides, which may act as transporter molecules that specifically recognize proteoglycans, in particular, chondroitin-4-sulfate (C4S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C4S expressing cells in vitro and in vivo.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: June 27, 2017
    Assignee: PHI PHARMA SA
    Inventors: Christophe Bonny, Fabrice Chenaux